In a recent preprint study encompassing over 40,000 patients, Eli Lilly's Mounjaro (tirzepatide) exhibited superior efficacy in weight loss compared to Novo Nordisk's Ozempic (semaglutide).
The study scrutinized 41,223 Electronic Health Records (EHRs) of overweight or obese patients prescribed either Mounjaro (tirzepatide) or Ozempic (semaglutide) for managing Type 2 diabetes. It focused on patients with accessible weight data and those who hadn't previously used a glucagon-like peptide-1 receptor agonist before May 2022.
Despite approximately 77% of the patients being on Ozempic (semaglutide), the findings revealed that individuals taking Mounjaro (tirzepatide) "demonstrated significantly higher likelihoods of achieving weight loss milestones of 5%, 10%, and 15%. Moreover, they experienced more substantial reductions in weight at 3, 6, and 12 months," as stated in the study.
Conducted by Truveta, a healthcare data company gathering EHR information from over 30 systems, this research marks the initial real-world comparative effectiveness analysis between Mounjaro (tirzepatide) and Ozempic (semaglutide). Truveta highlighted this in a news release on November 27.
Dr. Tyler Gluckman, the medical director of Providence St. Joseph Health's Center for Cardiovascular Analytics, Research, and Data Science and a co-author of the study, remarked in the release, "Evaluating the real-world impact of semaglutide and tirzepatide on weight loss offers insight into what we might expect with the recently approved obesity drug tirzepatide (marketed as Zepbound) and its potential comparison with semaglutide (marketed as Wegovy)."
Learn more about these groundbreaking drugs at our website by clicking below.
Citation